Meeting
2016 ASCO Annual Meeting
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Authors
Yan Wang
Fudan University ZhongShan Hospital, 180 Fenglin Road, Shanghai, Shanghai, China
Yan Wang , Yiyi Yu , Rongyuan Zhuang , Shan Yu , Jun Hou , Yuan Ji , Yihong Sun , Kuntang Shen , Zhenbin Shen , Fenglin Liu , Naiqing Zhao , Tianshu Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4047)
DOI
10.1200/JCO.2016.34.15_suppl.4047
Abstract #
4047
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Comparison of efficacy and tolerance of first-line palliative chemotherapy EOX and mDCF regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors.
First Author: Sebastian Ochenduszko
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz
Poster
2021 ASCO Annual Meeting
Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
First Author: Weijian Guo
Poster
2018 ASCO Annual Meeting
Oxaliplatin plus capecitabine (XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC).
First Author: Tianshu Liu